Our Pricing

Lowest Price Mounjaro in the UK - Reviews & Orders

Published on: June 03, 2026

Searching for the lowest price Mounjaro UK pharmacy with transparent costs and genuine licensed medication? At Cured Pharmacy, Mounjaro (tirzepatide) KwikPens start from £124.99 with pricing confirmed upfront before your free online consultation. Our UK-registered clinical team provides prescription assessment in under three minutes, and all pens are dispensed by our GPhC-registered pharmacy with discreet next-day delivery across the UK.

How Mounjaro Works for Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments such as semaglutide, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure.

In the SURPASS-3 clinical trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks—significantly greater than comparator therapies [1]. The dual-agonist mechanism also improved glycaemic control and cardiovascular risk markers in study populations [2].

Mounjaro is administered once weekly via a pre-filled KwikPen injection device. Treatment begins at a low starter dose (2.5mg) and is gradually titrated upward every four weeks to minimise gastrointestinal side effects, which are the most commonly reported adverse events during the initial escalation phase [3].

Mounjaro Pricing and Dosing at Cured Pharmacy

At Cured Pharmacy, Mounjaro KwikPens are priced from £124.99 with the final cost determined by your prescribed maintenance dose following clinical assessment. All pricing is displayed transparently before you begin the consultation process, ensuring no hidden fees or unexpected charges.

Your UK prescriber will review your medical history, current medications, weight loss goals, and any contraindications during the free online consultation. Based on this assessment, they will determine the appropriate starting dose and escalation schedule tailored to your individual circumstances.

Each Mounjaro pen contains four doses for once-weekly administration. Doses range from 2.5mg (starter) through 5mg, 7.5mg, 10mg, 12.5mg, to the maximum licensed dose of 15mg. Prescribers typically increase the dose every four weeks, subject to tolerability and clinical response [3].

Transparent Pricing Before Consultation

Unlike many online providers, Cured Pharmacy displays exact treatment costs upfront, allowing you to make an informed decision before completing your medical assessment. This commitment to transparency reflects our broader ethos: no surprise fees, no pressure sales, and no obligation to proceed if the treatment isn't suitable for you.

Mounjaro vs Wegovy: Clinical Comparison

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are injectable GLP-1-based treatments licensed by the MHRA for chronic weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity. However, their mechanisms and clinical outcomes differ meaningfully.

Wegovy is a selective GLP-1 receptor agonist, whereas Mounjaro is a dual GIP/GLP-1 receptor agonist. In head-to-head trials, tirzepatide demonstrated superior weight reduction compared to semaglutide at comparable timepoints [4]. The STEP 1 trial showed semaglutide 2.4mg achieved an average 14.9% body weight reduction at 68 weeks, while SURPASS-3 reported 22.5% reduction with tirzepatide 15mg at 72 weeks [1][2].

Both medications require once-weekly subcutaneous injection and share similar side effect profiles, predominantly gastrointestinal symptoms such as nausea, vomiting, and diarrhoea during dose escalation. Your prescriber will assess which treatment aligns best with your clinical profile, tolerance, and cost considerations.

Which Treatment Is Right for You?

Choosing between Mounjaro and Wegovy depends on multiple factors including your weight loss target, previous treatment response, budget, and medical history. Some patients may respond better to one mechanism over another, and tolerability varies individually. Your UK prescriber at Cured Pharmacy will discuss these variables during your consultation to recommend the most appropriate option, subject to clinical suitability.

Real Patient Reviews: Mounjaro Experiences in the UK

Patients using Mounjaro through Cured Pharmacy frequently report meaningful weight loss within the first 12 weeks of treatment, alongside improved energy levels and reduced food cravings. Many describe the once-weekly injection schedule as convenient compared to daily alternatives, and the KwikPen device is generally well-tolerated by injection-naïve users.

Common early experiences include mild to moderate nausea during the first few weeks, particularly after dose increases. These symptoms typically resolve as the body adapts to the medication. Patients who maintain adequate hydration, eat smaller meals, and avoid high-fat foods during escalation phases report better tolerability [5].

Long-term users often highlight sustained weight loss beyond six months, with many achieving clinically significant reductions (≥10% body weight) that improve comorbid conditions such as hypertension, dyslipidaemia, and obstructive sleep apnoea. However, individual results vary, and Mounjaro is most effective when combined with dietary modification and increased physical activity.

How to Order Mounjaro from Cured Pharmacy

Ordering Mounjaro from Cured Pharmacy is straightforward and fully compliant with UK prescribing regulations. Begin by completing our free online consultation, which takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications.

Your responses are reviewed by a UK-registered prescriber (doctor or independent prescriber) who will assess your clinical suitability for Mounjaro. If approved, your prescription is issued electronically and sent directly to our GPhC-registered pharmacy (registration number 9012511) for dispensing. If Mounjaro is not suitable, the prescriber may recommend an alternative treatment or advise you to consult your GP.

Once dispensed, your medication is packaged discreetly and dispatched via next-day courier to your chosen UK address. All orders are tracked, and our clinical team remains available for follow-up queries or dose adjustment requests throughout your treatment journey.

Prescription Requirements and Clinical Assessment

Mounjaro is a prescription-only medicine (POM) in the UK and cannot be supplied without a valid prescription from a UK-registered prescriber. Our clinical assessment ensures the treatment is safe and appropriate for your individual circumstances, in line with MHRA guidance and NICE recommendations for obesity management [6]. All prescribers at Cured Pharmacy are registered with the General Pharmaceutical Council (GPhC) or General Medical Council (GMC) and operate under the supervision of our superintendent pharmacist, Tarun Kumar (GPhC 2233073).

Mounjaro Side Effects and Safety Considerations

The most frequently reported side effects of Mounjaro are gastrointestinal, including nausea (occurring in up to 20% of users), vomiting, diarrhoea, constipation, and abdominal discomfort [3]. These symptoms are typically mild to moderate, occur most commonly during dose escalation, and diminish over time as tolerance develops.

Rarer but more serious adverse events include pancreatitis, gallbladder disease, acute kidney injury (usually secondary to dehydration from vomiting or diarrhoea), and hypoglycaemia when used concurrently with insulin or sulfonylureas. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use Mounjaro due to potential thyroid C-cell tumour risk observed in rodent studies [7].

Your prescriber will review your full medical history to identify any contraindications before issuing a prescription. If you experience severe or persistent side effects during treatment, contact our clinical team immediately or seek urgent medical attention if symptoms are acute. Regular monitoring and dose adjustment can often mitigate tolerability issues while maintaining therapeutic efficacy.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/14508 [accessed 13 August 2026]
4. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
5. Nauck, M. A., D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 21(1), 169. https://doi.org/10.1186/s12933-022-01604-7 [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating obesity [ID6279]. NICE Technology Appraisal Guidance. Retrieved from https://www.nice.org.uk/guidance/indevelopment/gid-ta11235 [accessed 13 August 2026]
7. Medicines and Healthcare products Regulatory Agency. (2023). Tirzepatide (Mounjaro): Risk of thyroid C-cell tumours. Drug Safety Update, 16(9). Retrieved from https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and no treatment guarantees specific outcomes.